tailieunhanh - Clinical and economic impact of ‘ROS1- testing’ strategy compared to a ‘no-ROS1-testing’ strategy in advanced NSCLC in Spain

Detection of the ROS1 rearrangement is mandatory in patients with advanced or metastatic non-small cell lung cancer (NSCLC) to allow targeted therapy with specific inhibitors. However, in Spanish clinical practice ROS1 determination is not yet fully widespread. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN